Zalemark Holding Company Inc. Signed Licensing Agreement with Lupos (Canada) Biotechnology Inc.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Details
News Market Reaction – ZMRK
The recorded move for ZMRK in the trading session of this news was +9.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORNONTO, ON / ACCESSWIRE / March 15, 2021 / Zalemark Holding Company Inc.(OTC PINK:ZMRK) signed Licensing Agreement with Lupos (Canada) Biotechnology Inc. to develop Cannabis topical products. This agreement will bring Zalemark in a position to market the cannabis products under their own registered "Aeroponleaf" trademark.
"We are excited to work with Lupos!" said Xia Wu, CEO of Zalemark. "Teaming up with Lupos to engage the cannabis topical products is an exciting development for our company".
"As a leading manufacturer of topicals products for the legal Canadian cannabis market, Lupos is thrilled to work with Zalemark to bring unique and innovative cannabis-based topicals to the Canadian market" said Dr. Nan Li, Founder and Chair of Lupos.
This agreement reflects Zalemark's desire to collaborate with companies that share the same visions of future of cannabis products. It also underscores Zalemark's commitment to its shareholders about cannabis products development.
Zalemark will be working closely to implement the plan. As the plan unfolds, the management team will deliver more information.
Forward Looking Statements
Information in this press release may contain ‘forward-looking statements.' Statements describing objectives or goals or the Company's future plans are also forward-looking statements and are subject to risks and uncertainties, including the financial performance of the Company and market valuations of its stock, which could cause actual results to differ materially from those anticipated. Forward-looking statements in this news release are made pursuant to the ‘Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to sales, acceptance of Zalemark Holding Company Inc.'s products, increased levels of competition, changes, dependence on intellectual property rights and other risks detailed from time to time in Zalemark Holding Company Inc. periodic reports filed with the regulatory authorities.
Email: info@zmarkholding.com
SOURCE: Zalemark Holding Company Inc.
View source version on accesswire.com:
https://www.accesswire.com/635409/Zalemark-Holding-Company-Inc-Signed-Licensing-Agreement-with-Lupos-Canada-Biotechnology-Inc